title: Methylation status of TRAF2 is associated with the diagnosis and prognosis of gastric cancer.
abstract: The purpose was to investigate whether the expression level of TRAF2 gene was regulated by DNA methylation and explore the role of TRAF2 methylation in the diagnosis and prognosis of gastric cancer (GC). Firstly, we detected the expression of TRAF2 both at mRNA level and protein level. And the up-regulated of TRAF2 expression at two different levels were both found (P<0.001). Then we measured the methylated status of TRAF2 by MSP and got a result of that TRAF2 was hypomethylated in GC patients compared with healthy controls (P<0.001). Meanwhile, the relationship between TRAF2 methylation and clinicopathologic characteristics was estimated through chi-square. The outcome proved that TRAF2 methylation was impacted by age (P=0.024), lymph node metastasis (P=0.046), TNM stage (P=0.021), distant metastasis (P=0.002) and depth of invasion (P=0.002). The AUC of 0.795 accompanying a sensitivity of 66.7% and a specificity of 94.7% were obtained from Receiver Operating Characteristic (ROC) curve which indicated the diagnostic value of TRAF2 methylation was high. At last, we researched the prognostic value of TRAF2 methylation. Kaplan-Meier showed that patients with TRAF2 hypomethylation had lived much shorter than those with TRAF2 hypermethylation (log rank test, P<0.001). Cox regression analysis revealed TRAF2 hypomethylation (HR=18.827, 95% CI=3.103-114.222, P=0.001), lymph node metastasis (HR=0.154, 95% CI=0.047-0.512, P=0.002), distant metastasis (HR=3.032, 95% CI=1.116-8.237, P=0.030), as well as differentiation (HR=0.287, 95% CI=0.113-0.731, P=0.009) were all vital prognostic factors in GC. Taken together, TRAF2 expression was increased in GC patients by DNA hypomethylation and this methylation could be an independent diagnostic and prognostic indicator in GC.
authors.affiliation: Department of Gastrogenterology, Huai'an First People's Hospital, Nanjing Medical University Huai'an, Jiangsu, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Gastrogenterology, Huai'an First People's Hospital, Nanjing Medical University Huai'an, Jiangsu, China.
authors.forename: Wei-Jie
authors.initials: WJ
authors.lastname: Dai
authors.affiliation: Department of Gastrogenterology, Huai'an First People's Hospital, Nanjing Medical University Huai'an, Jiangsu, China.
authors.forename: Xiao-Zhong
authors.initials: XZ
authors.lastname: Yang
mesh_terms: D000367:Age Factors; D000368:Aged; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D019175:DNA Methylation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000235:genetics; D012372:ROC Curve; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D047992:TNF Receptor-Associated Factor 2 / Q000235:genetics*; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D047992:TNF Receptor-Associated Factor 2
keywords: TRAF2; diagnosis and prognosis; gastric cancer; hypomethylation
references.citation: Oncogene. 2015 Jan 8;34(2):209-16
references.pmid: 24362534
references.citation: Oncol Rep. 2014 May;31(5):2085-92
references.pmid: 24677135
references.citation: Am J Clin Oncol. 1997 Aug;20(4):348-53
references.pmid: 9256887
references.citation: Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):94-8
references.pmid: 23392805
references.citation: Cancer Treat Rev. 2014 Jul;40(6):692-700
references.pmid: 24656602
references.citation: Medicine (Baltimore). 2014 Oct;93(19):e107
references.pmid: 25340495
references.citation: Tumour Biol. 2013 Aug;34(4):2127-33
references.pmid: 23504555
references.citation: Tumori. 2010 Sep-Oct;96(5):726-33
references.pmid: 21302620
references.citation: Genet Mol Res. 2014;13(2):4140-5
references.pmid: 24938706
references.citation: Tumour Biol. 2015 Jan;36(1):129-41
references.pmid: 25501508
references.citation: Curr Opin Genet Dev. 2010 Jun;20(3):290-8
references.pmid: 20359882
references.citation: Tumour Biol. 2014 Feb;35(2):1107-11
references.pmid: 24014049
references.citation: Oncol Lett. 2015 Apr;9(4):1502-1508
references.pmid: 25788990
references.citation: Arch Pathol Lab Med. 2014 Nov;138(11):1466-73
references.pmid: 25357107
references.citation: Dtsch Arztebl Int. 2011 Oct;108(41):698-705; quiz 706
references.pmid: 22114638
references.citation: J Biomed Biotechnol. 2010;2010:721485
references.pmid: 20300551
references.citation: J Biol Chem. 2009 Apr 17;284(16):10774-82
references.pmid: 19224920
references.citation: Oncogene. 2010 Oct 28;29(43):5761-71
references.pmid: 20802530
references.citation: Cancer Sci. 2010 Jan;101(1):36-45
references.pmid: 19891661
references.citation: World J Gastroenterol. 2014 Oct 14;20(38):13791-803
references.pmid: 25320517
references.citation: Cancer Cell. 2012 Jul 10;22(1):9-20
references.pmid: 22789535
references.citation: Neuroimmunomodulation. 2013;20(3):177-83
references.pmid: 23595117
references.citation: J Biol Chem. 2011 Nov 4;286(44):38466-77
references.pmid: 21921033
references.citation: Mini Rev Med Chem. 2010 Oct;10(11):1034-8
references.pmid: 20716059
references.citation: Nat Immunol. 2011 Aug;12(8):695-708
references.pmid: 21772278
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: BMC Cancer. 2007;7:120
references.pmid: 17608924
references.citation: Biochem Biophys Res Commun. 2013 Jun 28;436(2):344-8
references.pmid: 23743189